Apotex Suffers Defeat In Acular Dispute

Law360, New York (September 11, 2007, 12:00 AM EDT) -- In a major setback for Apotex Inc., a federal judge has found that the Canadian drug maker’s application for a generic version of anti-inflammatory eye treatment Acular infringed a patent held by Roche Palo Alto LLC and licensed to Allergan LLC.

Judge Martin J. Jenkins of the U.S. District Court for the Northern District of California on Tuesday granted summary judgment in favor of plaintiffs Roche and Allergan, finding that Apotex’s abbreviated new drug application (ANDA) violated the Acular patent, and that the patent was valid...
To view the full article, register now.